Angiotensin-(1-7)
Angiotensin-(1-7)
Evidence & Status
- Moderate Evidence
- Moderate
At a Glance
An investigational heptapeptide of the renin-angiotensin system.
Plain English
Human research is study-specific and does not establish a general treatment or dosing recommendation.
Overview
A biologically active heptapeptide formed through multiple pathways within the renin-angiotensin system. It is investigational and has no approved therapeutic indication.
Research Summary
Direct human administration and clinical research are study-specific. Published and registered-trial sources support investigational context only; they do not establish general dosing, a universal half-life, outpatient use, or an approved therapeutic indication.
Research Areas
- Cardiovascular protection
- Anti-fibrotic effects
- Insulin sensitivity
- ACE2/RAS axis
- Pulmonary disease
- COVID-19 pathophysiology
Safety & Risks
Serious Risks
- Hypotension in susceptible individuals
- Limited human safety data for chronic exogenous administration
- Rapid enzymatic degradation limits predictable dosing
Reported Side Effects
- Vasodilation (flushing, hypotension)
- Mild bradycardia
- Transient headache
Legal Status by Region
- United States
- Research only (investigational)
- United Kingdom
- Research only
- Australia
- Research only
- Canada
- Research only
Citations & Sources
- Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone
Clinical Cancer Research · 2009
PMID 19920106 · DOI 10.1158/1078-0432.CCR-09-1957
- Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial
2024
PMID 39231898 · DOI 10.1186/s13613-024-01369-0
- Use of Angiotensin-(1-7) in COVID-19
Registry NCT04633772
- Novel Experimental COVID-19 Therapies Affecting Host Response
Registry NCT04924660
- Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
Registry NCT06482853